Cargando…
Immuno-psychiatry: an agenda for clinical practice and innovative research
BACKGROUND: The diagnostic scheme for psychiatric disorders is currently based purely on descriptive nomenclature given that biomarkers subtypes and clearly defined causal mechanisms are lacking for the vast majority of disorders. The emerging field of “immuno-psychiatry” has the potential to widen...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084344/ https://www.ncbi.nlm.nih.gov/pubmed/27788673 http://dx.doi.org/10.1186/s12916-016-0712-5 |
_version_ | 1782463361551695872 |
---|---|
author | Leboyer, Marion Berk, Michael Yolken, Robert H. Tamouza, Ryad Kupfer, David Groc, Laurent |
author_facet | Leboyer, Marion Berk, Michael Yolken, Robert H. Tamouza, Ryad Kupfer, David Groc, Laurent |
author_sort | Leboyer, Marion |
collection | PubMed |
description | BACKGROUND: The diagnostic scheme for psychiatric disorders is currently based purely on descriptive nomenclature given that biomarkers subtypes and clearly defined causal mechanisms are lacking for the vast majority of disorders. The emerging field of “immuno-psychiatry” has the potential to widen the exploration of a mechanism-based nosology, possibly leading to the discovery of more effective personalised treatment strategies. DISCUSSION: Disturbances in immuno-inflammatory and related systems have been implicated in the aetiology, pathophysiology, phenomenology and comorbidity of several psychiatric disorders, including major mood disorders and schizophrenia. A fundamental challenge in their clinical management is to identify bio-signatures that might indicate risk, state, trait, prognosis or theragnosis. Here, we provide the rationale for a clinical and research agenda to refine future clinical practice and conceptual views, and to delineate pathways toward innovative treatment discovery. CONCLUSION: The development of bio-signatures will allow clinicians to tailor interventions to the abovementioned biomarker subtypes – a major translational goal for research in this field. |
format | Online Article Text |
id | pubmed-5084344 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-50843442016-10-28 Immuno-psychiatry: an agenda for clinical practice and innovative research Leboyer, Marion Berk, Michael Yolken, Robert H. Tamouza, Ryad Kupfer, David Groc, Laurent BMC Med Opinion BACKGROUND: The diagnostic scheme for psychiatric disorders is currently based purely on descriptive nomenclature given that biomarkers subtypes and clearly defined causal mechanisms are lacking for the vast majority of disorders. The emerging field of “immuno-psychiatry” has the potential to widen the exploration of a mechanism-based nosology, possibly leading to the discovery of more effective personalised treatment strategies. DISCUSSION: Disturbances in immuno-inflammatory and related systems have been implicated in the aetiology, pathophysiology, phenomenology and comorbidity of several psychiatric disorders, including major mood disorders and schizophrenia. A fundamental challenge in their clinical management is to identify bio-signatures that might indicate risk, state, trait, prognosis or theragnosis. Here, we provide the rationale for a clinical and research agenda to refine future clinical practice and conceptual views, and to delineate pathways toward innovative treatment discovery. CONCLUSION: The development of bio-signatures will allow clinicians to tailor interventions to the abovementioned biomarker subtypes – a major translational goal for research in this field. BioMed Central 2016-10-28 /pmc/articles/PMC5084344/ /pubmed/27788673 http://dx.doi.org/10.1186/s12916-016-0712-5 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Opinion Leboyer, Marion Berk, Michael Yolken, Robert H. Tamouza, Ryad Kupfer, David Groc, Laurent Immuno-psychiatry: an agenda for clinical practice and innovative research |
title | Immuno-psychiatry: an agenda for clinical practice and innovative research |
title_full | Immuno-psychiatry: an agenda for clinical practice and innovative research |
title_fullStr | Immuno-psychiatry: an agenda for clinical practice and innovative research |
title_full_unstemmed | Immuno-psychiatry: an agenda for clinical practice and innovative research |
title_short | Immuno-psychiatry: an agenda for clinical practice and innovative research |
title_sort | immuno-psychiatry: an agenda for clinical practice and innovative research |
topic | Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084344/ https://www.ncbi.nlm.nih.gov/pubmed/27788673 http://dx.doi.org/10.1186/s12916-016-0712-5 |
work_keys_str_mv | AT leboyermarion immunopsychiatryanagendaforclinicalpracticeandinnovativeresearch AT berkmichael immunopsychiatryanagendaforclinicalpracticeandinnovativeresearch AT yolkenroberth immunopsychiatryanagendaforclinicalpracticeandinnovativeresearch AT tamouzaryad immunopsychiatryanagendaforclinicalpracticeandinnovativeresearch AT kupferdavid immunopsychiatryanagendaforclinicalpracticeandinnovativeresearch AT groclaurent immunopsychiatryanagendaforclinicalpracticeandinnovativeresearch |